| |
|
|
|
Xtalks, Online
2025-03-31
Antibody-dependent cell-mediated cytotoxicity (ADCC) is a critical mechanism in antibody therapeutics, enabling the immune system to eliminate cancerous or infected cells. ADCC activity is heavily dependent on glycan patterns, particularly Fc fucosylation levels. Even a 1 percent change in affucosylation makes a significant difference for ADCC. This underscores the immense therapeutic potential of glycosylation control, although replicating and optimizing glycan patterns remains a significant challenge in antibody development for researchers, biopharma companies and contract development and manufacturing organizations (CDMOs).
This webinar will explore how glycoengineering solutions are transforming antibody development by enabling precise control of glycan profiles to optimize ADCC activity. Attendees will gain insights into how innovative technologies streamline workflows, maintain productivity and meet the challenges of scalable production processes. The session will also highlight how these advancements can accelerate the development of biosimilars and next-generation antibody therapeutics.
A major advantage of these technologies is their ability to meet diverse development needs. Biosimilar developers can precisely match originator glycoprofiles to ensure regulatory compliance and therapeutic equivalence, while innovators can use precise glycosylation control to design next-generation antibodies with enhanced functionality. These versatile solutions enable the production of afucosylated antibodies to boost ADCC activity or fully fucosylated antibodies for antibody-drug conjugates (ADCs).
GlymaxX® technology exemplifies the impact of glycoengineering. By enabling up to 99 percent afucosylation, it significantly enhances ADCC activity. Its unique ability to adjust fucosylation levels offers unparalleled flexibility, allowing biopharma companies to produce innovative and potent therapeutics. This proven technology has been applied in late-stage clinical trials and contributed to the FDA approval of antibodies such as zanidatamab and zenocutuzumab.
Join this webinar to discover how precision glycoengineering can help overcome glycan modulation challenges, optimize ADCC and unlock the full potential of antibody portfolios. Register today to learn how these advancements improve therapeutic outcomes and streamline development processes.
Keywords: Drug Development, Antibody, Clinical Research, CRO, Biosimilars, Biotherapeutics, Clinical Data, Therapeutic Areas, Antibody Drug, Monoclonal Antibody, Therapeutic Antibody Development, CDMO/CMO
|
|
|
|
|
|
|
|
Organized by:
|
|
Xtalks |
|
|
Invited Speakers:
|
|
Dr. Volker Sandig, Chief Scientific Officer, ProBioGen
|
|
|
|
|
|
|
|
Deadline for Abstracts:
|
|
2025-03-31
|
|
|
|
|
|
|
|
Registration:
|
|
Free Registration
|
|
|
E-mail:
|
|
tristan@xtalks.com
|
|
|
|
|
|
|
|
|
|
|
|
|